Navigation Links
Clinical Results Presented for Trovagene's Urine-Based High-Risk HPV Assay.
Date:8/25/2014

SEATTLE, Aug. 25, 2014 /PRNewswire/ -- Trovagene, Inc. (NASDAQ:   TROV), a developer of cell-free molecular diagnostics, announced today that results from two independent clinical studies were presented at the 29th International Papillomavirus (IPV) Conference. Results from both pilot studies consistently demonstrated that the Company's urine-based assay for the detection of high-risk HPV had high sensitivity (greater than 90%) for identifying women with high grade cervical intraepithelial neoplasia (CIN2/3). Assay performance was comparable to traditional HPV testing with commercially available tests in patient-matched cervical samples. In one of these studies, urine collection has been examined to establish standardization of urine as a clinical specimen for high-risk HPV testing.

In an oral presentation entitled "Evaluation of Two Urine-Based HPV Assays In Comparison to Cervical HPV Detection and High-Grade CIN Among Women Attending a Colposcopy Clinic," results from a population-based National Cancer Institute study, conducted at the University of Oklahoma Health Sciences Center, were released.  A total of 72 women with abnormal cervical cancer screening results were referred to a colposcopy clinic. Urine samples had been collected from each patient prior to undergoing a pelvic exam to obtain a cervical sample.  In urine samples, Trovagene's HR-HPV assay was superior to a commercially available HPV test for the identification of high-risk HPV positive women with CIN2/3.  When comparing patient-matched urine samples with cervical specimens for the identification of high-risk HPV positive women with CIN2/3, Trovagene's HR-HPV assay was comparable to traditional HPV testing from cervical specimens.

A second presentation entitled "A Comparison of Urine Collection Times for the Detection of High-Risk HPV Infection in Women" included results from a study conducted at University of North Carolina, Cha
'/>"/>

SOURCE Trovagene, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Regado Biosciences Permanently Halts REGULATE-PCI Clinical Trial
2. ACI Clinical: Innovation and Savings in Data Safety Monitoring Committees
3. KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema
4. Luoxis Announces Presentation of Positive Clinical Findings from Five-Year Clinical Study of Traumatic Brain Injury and Oxidation-Reduction Potential at 2014 American Academy of Surgical Trauma Meeting
5. DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer
6. Coherus Announces CHS-1420 (Investigational Adalimumab Biosimilar) Meets Primary Endpoint In Pivotal Pharmacokinetic Clinical Study
7. Immune Pharmaceuticals Announces Second Quarter 2014 Financial Results and Provides Update on Bertilimumab Commencement of Phase II Clinical Trials
8. Major Clinical Study Supports NIPT As First Line Screening Test For All Pregnant Women
9. VolitionRx Invests in Laboratory Automation System to Increase Throughput Capacity for Large Clinical Trials
10. Rock Creek Pharmaceuticals Reports Second Quarter and Announces Clinical Update
11. BioSpecifics Technologies Corp. Announces Initiation of Phase 2 Clinical Study of CCH for Treatment of Lipoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... 23, 2014 According to ... Product (Radiofrequency, Ultrasound, Irreversible Electroporation, Cryotherapy, Microwave), Application ... - Global Forecasts to 2019", published by MarketsandMarkets, studies ... period of 2014 to 2019. The market is ... CAGR of 9.6% from 2014 to 2019. ...
(Date:9/23/2014)... , Sept. 23, 2014 A case report ... a SynCardia temporary Total Artificial Heart into a patient ... ventricles were reversed, along with other abnormalities. ... modifying the SynCardia Total Artificial Heart to treat a ... report and video in the Journal of Visualized Experiments ...
(Date:9/23/2014)... Calif. , Sept. 23, 2014  Savant ... today confirmed the initiation of human safety testing ... of addiction. A single dose of 18-MC, administered ... study conducted by Savant,s South American partner, was ... drug. Savant HWP plans to develop 18-MC as ...
Breaking Medicine Technology:Ablation Technologies Market Worth $3.81 Billion by 2019 2Ablation Technologies Market Worth $3.81 Billion by 2019 3Ablation Technologies Market Worth $3.81 Billion by 2019 41st Use of the SynCardia Total Artificial Heart in a 17-Year-Old Congenital Heart Disease Patient at Pediatric Hospital 21st Use of the SynCardia Total Artificial Heart in a 17-Year-Old Congenital Heart Disease Patient at Pediatric Hospital 31st Use of the SynCardia Total Artificial Heart in a 17-Year-Old Congenital Heart Disease Patient at Pediatric Hospital 4Savant HWP Confirms Initiation of a Human Safety Trial for 18-MC, a Potential Anti-Addiction Therapy 2Savant HWP Confirms Initiation of a Human Safety Trial for 18-MC, a Potential Anti-Addiction Therapy 3
... March 15, 2011 Omeros Corporation (Nasdaq: ... and commercializing products focused on inflammation, bleeding and disorders ... for the fourth quarter and year ended December 31, ... for the three months ended December 31, 2010 were ...
... Pharmacy Benefit Consulting, the nation,s leading Pharmacy Benefit ... their clients. On February 16th, ARMSRx ... Lumber.  It was recommended and modeled by ARMSRx last ... making some simple changes.  The results speak for themselves. ...
Cached Medicine Technology:Omeros Corporation Reports Fourth Quarter and Year-End 2010 Financial Results 2Omeros Corporation Reports Fourth Quarter and Year-End 2010 Financial Results 3Omeros Corporation Reports Fourth Quarter and Year-End 2010 Financial Results 4Omeros Corporation Reports Fourth Quarter and Year-End 2010 Financial Results 5Omeros Corporation Reports Fourth Quarter and Year-End 2010 Financial Results 6ARMSRx and 84 Lumber Hammer Down Rx Costs...Again 2
(Date:9/23/2014)... Mich. They are common suggestions to remedy stress: You ... Get out and see people. , Turns out ... better a lot better a new large scale ... lower depression, less perceived stress and enhanced mental health and ... Michigan, with partners from De Montfort University, James Hutton Institute, ...
(Date:9/23/2014)... ANGELES (September 23, 2014) Laparoscopic cholecystectomy, a minimally ... the most common abdominal surgeries in the U.S. Yet ... to the procedure with some moving patients quickly into ... online Monday in the American Journal of Surgery ... regular working hours rather than rushing the patients into ...
(Date:9/23/2014)... living things function comes from knowledge of structuresatomic details ... receptors that are docking stations for viruses and messenger ... carry genetic blueprints for building cellular machinery, to name ... structural details, a new grant just awarded by the ... of Energy (DOE) will fund the operation of a ...
(Date:9/23/2014)... ADOMANI, Inc. has announced that industry expert ... is a 13-year veteran in the school, commercial and transit ... Bus Sales of Colton, California. While with A-Z Mr. Reynolds ... line revenues, profit and market penetration by double digits. , ... all-electric or plug-in hybrid vehicle conversions. They have converted ...
(Date:9/23/2014)... the European Journal of Cancer presents detailed ... the 1st EORTC Cancer Survivorship Summit held this past ... and more personalized multimodal treatments has boosted survival rates ... and rapidly increasing number of cancer survivors. Despite this ... broad spectrum of late adverse treatment effects and some ...
Breaking Medicine News(10 mins):Health News:Beating stress outdoors? Nature group walks may improve mental health 2Health News:Study finds gallbladder surgery can wait 2Health News:New NIH/DOE grant for life science studies at NSLS-II 2Health News:New NIH/DOE grant for life science studies at NSLS-II 3Health News:ADOMANI Announces Jim Reynolds to Take Over as President and CEO 2
... disease are there, researchers say , WEDNESDAY, Oct. 24 (HealthDay ... show early signs of heart disease -- similar to that ... by a team at Washington University School of Medicine, St. ... the children had undergone cardiac ultrasound to check on symptoms ...
... break-through new way of ... taking daily dose of glucosamine, SAN FRANCISCO, Oct. 24 ... wants to help,people keep their joints hydrated and moving smoothly.* The ... Joint Juice products: -- Original Joint Juice: ready-to-drink juice-based dietary ...
... ), the,global leader in the development, manufacture and supply ... today that it,will broadcast a third quarter 2007 earnings ... 2007 at 10:00 a.m. EDT. The call will,last approximately ... the opportunity to listen to,the conference call live at ...
... FRANCISCO While some targeted therapies drugs ... pathways occurring within cancer cells work well by ... when teamed with other targeted and conventional therapies. ... Molecular Targets and Cancer Therapeutics, multiple-target applications of new ...
... Out of Pocket Expenses ... for Medical Foods, ... BMRN) announced today that it has,provided a $250,000 grant to the ... program for patients with,phenylketonuria (PKU), a rare genetic metabolic disorder. Funds ...
... 24 NutraCea (OTC Bulletin,Board: NTRZ), a health ... bran (SRB) nutrient research and technology whose products ... benefits for,humans and animals announced today that it ... relations services and an expanded,communications program among the ...
Cached Medicine News:Health News:Obesity Can Hurt Kids' Hearts 2Health News:Joint Juice Helps America Hydrate Its Joints* With New High Value Coupon Offer 2Health News:Joint Juice Helps America Hydrate Its Joints* With New High Value Coupon Offer 3Health News:MSA Schedules Third Quarter Earnings Webcast 2Health News:Combination targets: some drugs may work best when they work together 2Health News:Combination targets: some drugs may work best when they work together 3Health News:Combination targets: some drugs may work best when they work together 4Health News:Combination targets: some drugs may work best when they work together 5Health News:Combination targets: some drugs may work best when they work together 6Health News:Combination targets: some drugs may work best when they work together 7Health News:BioMarin Provides Grant to NORD to Expand PKU Patient Support Services 2Health News:BioMarin Provides Grant to NORD to Expand PKU Patient Support Services 3Health News:BioMarin Provides Grant to NORD to Expand PKU Patient Support Services 4Health News:BioMarin Provides Grant to NORD to Expand PKU Patient Support Services 5Health News:NutraCea Appoints Financial Relations Board as New Investor Relations Firm 2Health News:NutraCea Appoints Financial Relations Board as New Investor Relations Firm 3
... automated semen analysis, with accurate, consistent, reliable ... Automation provides standardization and ease of use ... analysis. SPERMALITE is a new-generation automated semen ... analysis, and a hard -copy analysis report ...
Stainless Steel. Sterile. 2 pieces/box...
... Cannulated Screw System is part ... systems developed by DePuy ACE ... 3.5mm to 8.0mm. Complete with ... system was designed with the ...
... The first FDA-cleared third-generation allergy test , ... blood testing. It provides quantitative determination of ... excellent precision, accuracy and lot-to-lot reproducibility. The ... hour to help you identify, monitor and ...
Medicine Products: